Hida, Toyoaki <br/><br/>
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.  [electronic resource] 

 -  Cancer science  Apr 2011 
 - 845-51 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1349-7006 
<br/><br/><label>Standard No.: </label>10.1111/j.1349-7006.2010.01839.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacokinetics<br/>Asian People<br/>Biomarkers, Tumor--analysis<br/>Carboplatin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Staging<br/>Paclitaxel--administration & dosage<br/>Remission Induction<br/>Survival Rate<br/>Tissue Distribution<br/>Treatment Outcome<br/>Xanthones--administration & dosage